Literature DB >> 19319678

Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease?

Morris H Baslow1, David N Guilfoyle.   

Abstract

Canavan disease (CD) is a genetic degenerative brain disorder associated with mutations of the gene encoding aspartoacylase (ASPA). In humans, the CD syndrome is marked by early onset, hydrocephalus, macroencephaly, psychomotor retardation, and spongiform myelin sheath vacuolization with progressive leukodystrophy. Metabolic hallmarks of the disease include elevated N-acetylaspartate (NAA) levels in brain, plasma and CSF, along with daily excretion of large amounts of NAA and its anabolic metabolite, N-acetylaspartylglutamate (NAAG). Of the observed neuropathies, the most important appears to be the extensive demyelination that interferes with normal neuronal signaling. However, finding the links between the lacks of ASPA activity in oligodendrocytes, the buildup of NAA in white matter (WM) and the mechanisms underlying the edematous spongiform leukodystrophy have remained elusive. In this analytical review we consider what those links might be and propose that in CD, the pathological buildup of NAA in limited WM extracellular fluid (ECF) is responsible for increased ECF osmotic-hydrostatic pressure and initiation of the demyelination process. We also hypothesize that NAA is not directly liberated by neurons in WM as it is in gray matter, and that its source in WM ECF is solely as a product of the catabolism of axon-released NAAG at nodes of Ranvier by astrocyte NAAG peptidase after it has docked with the astrocyte surface metabotropic glutamate receptor 3. This hypothesis ascribes for the first time a possible key role played by astrocytes in CD, linking the lack of ASPA activity in myelinating oligodendrocytes, the pathological buildup of NAA in WM ECF, and the spongiform demyelination process. It also offers new perspectives on the cause of the leukodystrophy in CD, and on possible treatment strategies for this inherited metabolic disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19319678     DOI: 10.1007/s11064-009-9958-z

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  50 in total

Review 1.  Physiological role of N-acetylaspartate: contribution to myelinogenesis.

Authors:  Robert W Ledeen; Jianfeng Wang; Gusheng Wu; Zi-Hua Lu; Goutam Chakraborty; Markus Meyenhofer; Stephen K Tyring; Reuben Matalon
Journal:  Adv Exp Med Biol       Date:  2006       Impact factor: 2.622

2.  Natural history of Canavan disease revealed by proton magnetic resonance spectroscopy (1H-MRS) and diffusion-weighted MRI.

Authors:  C G Janson; S W J McPhee; J Francis; D Shera; M Assadi; A Freese; P Hurh; J Haselgrove; D J Wang; L Bilaniuk; P Leone
Journal:  Neuropediatrics       Date:  2006-08       Impact factor: 1.947

3.  Fully-automated detection of cerebral water content changes: study of age- and gender-related H2O patterns with quantitative MRI.

Authors:  Heiko Neeb; Karl Zilles; N Jon Shah
Journal:  Neuroimage       Date:  2005-11-21       Impact factor: 6.556

4.  Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain.

Authors:  Raji Mathew; Peethambaran Arun; Chikkathur N Madhavarao; John R Moffett; M A Aryan Namboodiri
Journal:  J Pharmacol Exp Ther       Date:  2005-07-07       Impact factor: 4.030

Review 5.  Functions of N-acetyl-L-aspartate and N-acetyl-L-aspartylglutamate in the vertebrate brain: role in glial cell-specific signaling.

Authors:  M H Baslow
Journal:  J Neurochem       Date:  2000-08       Impact factor: 5.372

6.  Functional 1H-MRS findings in migraine patients with and without aura assessed interictally.

Authors:  Paola Sarchielli; Roberto Tarducci; Otello Presciutti; Gianni Gobbi; Gian Piero Pelliccioli; Giuseppe Stipa; Andrea Alberti; Giuseppe Capocchi
Journal:  Neuroimage       Date:  2005-01-05       Impact factor: 6.556

7.  Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.

Authors:  Maria Traka; Robert L Wollmann; Sonia R Cerda; Jason Dugas; Ben A Barres; Brian Popko
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

8.  Ultrasound findings in follow-up investigations in a case of aspartoacylase deficiency (canavan disease).

Authors:  N Breitbach-Faller; K Schrader; D Rating; R Wunsch
Journal:  Neuropediatrics       Date:  2003-04       Impact factor: 1.947

9.  Immunohistochemical localization of aspartoacylase in the rat central nervous system.

Authors:  Chikkathur N Madhavarao; John R Moffett; Roger A Moore; Ronald E Viola; M A Aryan Namboodiri; David M Jacobowitz
Journal:  J Comp Neurol       Date:  2004-05-03       Impact factor: 3.215

10.  The apparent dependence of the diffusion coefficient of N-acetylaspartate upon magnetic field strength: evidence of an interaction with NMR methodology.

Authors:  David N Guilfoyle; Raymond F Suckow; Morris H Baslow
Journal:  NMR Biomed       Date:  2003-12       Impact factor: 4.044

View more
  9 in total

1.  Redirecting N-acetylaspartate metabolism in the central nervous system normalizes myelination and rescues Canavan disease.

Authors:  Dominic J Gessler; Danning Li; Hongxia Xu; Qin Su; Julio Sanmiguel; Serafettin Tuncer; Constance Moore; Jean King; Reuben Matalon; Guangping Gao
Journal:  JCI Insight       Date:  2017-02-09

2.  Rescuing Canavan disease: engineering the wrong cell at the right time.

Authors:  Morris H Baslow
Journal:  J Inherit Metab Dis       Date:  2017-04-03       Impact factor: 4.982

Review 3.  Clinical applications involving CNS gene transfer.

Authors:  Boris Kantor; Thomas McCown; Paola Leone; Steven J Gray
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

Review 4.  Lipid metabolism in myelinating glial cells: lessons from human inherited disorders and mouse models.

Authors:  Roman Chrast; Gesine Saher; Klaus-Armin Nave; Mark H G Verheijen
Journal:  J Lipid Res       Date:  2010-11-09       Impact factor: 5.922

5.  Long-term follow-up after gene therapy for canavan disease.

Authors:  Paola Leone; David Shera; Scott W J McPhee; Jeremy S Francis; Edwin H Kolodny; Larissa T Bilaniuk; Dah-Jyuu Wang; Mitra Assadi; Olga Goldfarb; H Warren Goldman; Andrew Freese; Deborah Young; Matthew J During; R Jude Samulski; Christopher G Janson
Journal:  Sci Transl Med       Date:  2012-12-19       Impact factor: 17.956

Review 6.  Astrocytes: the missing link in neurologic disease?

Authors:  Chia-Ching John Lin; Benjamin Deneen
Journal:  Semin Pediatr Neurol       Date:  2013-10-16       Impact factor: 1.636

7.  Astroglial redistribution of aquaporin 4 during spongy degeneration in a Canavan disease mouse model.

Authors:  Tim Clarner; Nicola Wieczorek; Barbara Krauspe; Katharina Jansen; Cordian Beyer; Markus Kipp
Journal:  J Mol Neurosci       Date:  2013-11-24       Impact factor: 3.444

Review 8.  Canavan Disease as a Model for Gene Therapy-Mediated Myelin Repair.

Authors:  Anoushka Lotun; Dominic J Gessler; Guangping Gao
Journal:  Front Cell Neurosci       Date:  2021-04-23       Impact factor: 6.147

Review 9.  Astrocyte and Oligodendrocyte Cross-Talk in the Central Nervous System.

Authors:  Erik Nutma; Démi van Gent; Sandra Amor; Laura A N Peferoen
Journal:  Cells       Date:  2020-03-03       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.